AU2002254124A1 - Aryl-n-cyanoguanidines and methods related thereto - Google Patents

Aryl-n-cyanoguanidines and methods related thereto

Info

Publication number
AU2002254124A1
AU2002254124A1 AU2002254124A AU2002254124A AU2002254124A1 AU 2002254124 A1 AU2002254124 A1 AU 2002254124A1 AU 2002254124 A AU2002254124 A AU 2002254124A AU 2002254124 A AU2002254124 A AU 2002254124A AU 2002254124 A1 AU2002254124 A1 AU 2002254124A1
Authority
AU
Australia
Prior art keywords
methods
sub
compounds
cyanoguanidines
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002254124A
Other languages
English (en)
Inventor
Soumitra S. Ghosh
Tomas R. Szabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Migenix Corp
Original Assignee
Mitokor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitokor Inc filed Critical Mitokor Inc
Publication of AU2002254124A1 publication Critical patent/AU2002254124A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
AU2002254124A 2001-02-27 2002-02-27 Aryl-n-cyanoguanidines and methods related thereto Abandoned AU2002254124A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27236801P 2001-02-27 2001-02-27
US60/272,368 2001-02-27
PCT/US2002/006717 WO2002068381A2 (en) 2001-02-27 2002-02-27 Aryl-n-cyanoguanidines and methods related thereto

Publications (1)

Publication Number Publication Date
AU2002254124A1 true AU2002254124A1 (en) 2002-09-12

Family

ID=23039505

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002254124A Abandoned AU2002254124A1 (en) 2001-02-27 2002-02-27 Aryl-n-cyanoguanidines and methods related thereto

Country Status (9)

Country Link
US (4) US6562821B2 (cg-RX-API-DMAC7.html)
EP (1) EP1377282B1 (cg-RX-API-DMAC7.html)
JP (1) JP2004525906A (cg-RX-API-DMAC7.html)
AT (1) ATE336237T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002254124A1 (cg-RX-API-DMAC7.html)
CA (1) CA2475454A1 (cg-RX-API-DMAC7.html)
DE (1) DE60213958T2 (cg-RX-API-DMAC7.html)
ES (1) ES2271247T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002068381A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE336237T1 (de) * 2001-02-27 2006-09-15 Migenix Corp Aryl-n-cyanoguanidine derivate und deren verwendung
US7411000B2 (en) * 2001-03-15 2008-08-12 The Scripps Research Institute Process of inhibiting cell death in injured cartilage
AU2002357137A1 (en) * 2001-12-10 2003-06-23 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase
US7642092B2 (en) * 2003-03-03 2010-01-05 Technion Research & Development Foundation Ltd. Cultured cartilage/bone cells/tissue, method of generating same and uses thereof
CN111587117A (zh) * 2018-02-02 2020-08-25 白雁生物技术公司 用于预防或治疗类风湿性关节炎的、含线粒体的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265905A (en) 1975-09-30 1981-05-05 Merck & Co., Inc. Method of treating inflammation employing acyl cyanoguanidines
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
KR20020084273A (ko) 2000-03-31 2002-11-04 화이자 프로덕츠 인코포레이티드 신규한 피페라진 유도체
ATE336237T1 (de) * 2001-02-27 2006-09-15 Migenix Corp Aryl-n-cyanoguanidine derivate und deren verwendung

Also Published As

Publication number Publication date
ES2271247T3 (es) 2007-04-16
ATE336237T1 (de) 2006-09-15
US20050182057A1 (en) 2005-08-18
DE60213958D1 (de) 2006-09-28
WO2002068381A3 (en) 2002-10-31
US20080032981A1 (en) 2008-02-07
US6927218B2 (en) 2005-08-09
US20040067987A1 (en) 2004-04-08
US20030045556A1 (en) 2003-03-06
EP1377282B1 (en) 2006-08-16
JP2004525906A (ja) 2004-08-26
EP1377282A2 (en) 2004-01-07
US7230132B2 (en) 2007-06-12
US6562821B2 (en) 2003-05-13
WO2002068381A2 (en) 2002-09-06
DE60213958T2 (de) 2007-08-30
CA2475454A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
EA200200509A1 (ru) Новые производные бензоимидазола, используемые в качестве антипролиферативного средства
ATE260263T1 (de) Heteroaromatische bizyklische verbindungen mit antikrebswirkung
MY138252A (en) Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease
WO2003048164A3 (en) Adenosine a2a receptor antagonists
IL163629A0 (en) Glutaminyl derivatives and pharmaceutical compositions containing the same
EA200200716A1 (ru) Арилконденсированные азаполициклические соединения
EA200200106A1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
WO2004056786A3 (en) Pyrimidine derivates for the treatment of abnormal cell growth
WO2004045618A3 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
PT1427708E (pt) Derivados amino-ftalazinona activos como inibidors de cinase, processo para a sua preparação e composições farmacêuticas contendo-os
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
MXPA04003245A (es) Hidroxipropilaminas.
BR9408325A (pt) Composto composição farmacêutica e processo para a manufatura de um composto
CA2501799A1 (en) Pyrazole compounds for treatment of neurodegenerative disorders
AU2246292A (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
SI1696905T1 (sl) Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni
TW200502221A (en) Novel lactams and uses thereof
EP1177791A3 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
PL342614A1 (en) Anticarcinogenic drugs
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
TR199701497T1 (xx) Beyin �demini �nleyen terkip.
AU2002254124A1 (en) Aryl-n-cyanoguanidines and methods related thereto
EP1253139A3 (en) Multioligoanilinated fullerenes
DE60234024D1 (de) Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase